The big pharma is tapping into Muna’s MiND-MAP platform to gain extra validation for its own early-stage work in Alzheimer’s and other neurodegenerative conditions.

The company is keeping up a flow of deals in oncology, opening up access to a range of new modalities and potential future combinations with two new tie-ups.

The masked T-cell engager has produced eye-catching results in heavily pre-treated prostate cancer patients, and Janux is aiming to jump ahead of Novartis’s Pluvicto in treatment regimens.

Tolerability problems with a high dose of its multi-RAS inhibitor in NSCLC patients knocked shares, but Revolution is pressing on in this setting and in pancreatic cancer. It also has eye-catching early results in colorectal cancer.

The Chinese company is building on its success with ivonescimab and believes it can stay ahead of its rivals and develop into a global company.

As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.